Cardiomyocyte specific deletion of PP2A causes cardiac hypertrophy

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Biochemistry

Background:

• Cardiac hypertrophy is a pathological hallmark of heart disease.
• Serine/threonine protein phosphatases, including PP2A, regulate cardiac protein dephosphorylation.
• Dysregulation of these phosphatases is implicated in cardiac dysfunction.

Purpose of the Study:

• To investigate the role of Protein Phosphatase 2A (PP2A) in cardiac hypertrophy.
• To generate a cardiomyocyte-specific PP2A knockout mouse model.
• To establish a new mouse model for studying cardiac hypertrophy with myocardial fibrosis.

Main Methods:

• Generation of a tamoxifen-inducible cardiomyocyte-specific PP2A knockout mouse model using MerCreMer.
• Assessment of cardiac function via echocardiography.
• Molecular analysis of signaling pathways and gene expression in knockout mice.

Main Results:

• PP2A activity decrease leads to cardiomyocyte hypertrophy and fibrosis.
• Loss of PP2ACα results in heart failure, indicated by altered EF, FS, LV, ANP, and BNP.
• Knockout mice exhibit increased B55a and B56e expression and disturbed Akt/GSK3β/β-catenin pathway regulation.

Conclusions:

• Cardiomyocyte-specific deletion of the PP2A gene induces cardiac hypertrophy.
• The developed knockout mice serve as a valuable model for studying cardiac hypertrophy and myocardial fibrosis.
• PP2A plays a critical role in maintaining cardiac function and preventing pathological remodeling.